Ventolin hfa 90 mg
Pro Research Analysisby 
Searched over 200M research papers
Ventolin HFA 90 mg: Efficacy, Safety, and Clinical Comparisons
Introduction to Ventolin HFA 90 mg
Ventolin HFA (albuterol) is a widely used inhaler for the treatment of asthma and other respiratory conditions. It is formulated with hydrofluoroalkane (HFA) propellants, which are environmentally friendly alternatives to chlorofluorocarbon (CFC) propellants. This article synthesizes research findings on the efficacy, safety, and clinical comparisons of Ventolin HFA 90 mg.
Efficacy of Ventolin HFA 90 mg
Bronchodilator Effectiveness
Studies have shown that Ventolin HFA provides effective bronchodilation comparable to its CFC counterpart. In a 12-week randomized, double-blind trial, both Ventolin HFA and Ventolin CFC demonstrated significant improvements in forced expiratory volume (FEV1) over baseline, with no significant differences between the two formulations3 4. This indicates that switching from Ventolin CFC to Ventolin HFA does not compromise the bronchodilator efficacy.
Protection Against Bronchoconstriction
Research comparing the protective effects of Proventil-HFA and Ventolin-CFC against methacholine-induced bronchoconstriction found that both formulations were bioequivalent. The study concluded that 100- and 200-microgram doses of salbutamol from an MDI are sufficient for effective bronchoprotection1.
Safety Profile of Ventolin HFA 90 mg
Adverse Events and Tolerability
Multiple studies have assessed the safety of Ventolin HFA. A long-term study over 12 weeks reported that the adverse event rates for Ventolin HFA were similar to those for Ventolin CFC and placebo. No clinically meaningful changes in heart rate, blood pressure, or laboratory test results were observed, indicating that Ventolin HFA is well-tolerated during regular use2 3.
Safety in Pediatric Use
A study focusing on children aged 2 to less than 4 years found that Ventolin HFA was safe and well-tolerated. Although the study was not powered to achieve statistically significant outcomes, improvements in daytime asthma symptom scores and reduced rescue albuterol use were noted in the albuterol HFA groups compared to placebo6.
Clinical Comparisons and Patient Satisfaction
Comparison with Proventil HFA
Ventolin HFA and Proventil HFA have been shown to have similar safety and efficacy profiles. Both formulations provided comparable bronchodilation and asthma control over a 12-week period, with no significant differences in FEV1 efficacy variables4. This suggests that either formulation can be used interchangeably for effective asthma management.
Integrated Dose Counter
A novel MDI with an integrated dose counter was evaluated for its accuracy and patient satisfaction. The study found high concordance between counter readings, diary-recorded actuations, and canister weights. Patients expressed high satisfaction with the dose counter, with 92% agreeing that it would help prevent running out of medication5.
Conclusion
Ventolin HFA 90 mg is an effective and safe option for asthma management, providing comparable bronchodilation to its CFC counterpart and other HFA formulations. It is well-tolerated in both adults and young children, with a safety profile similar to placebo. The integrated dose counter in Ventolin HFA inhalers enhances patient satisfaction by accurately tracking medication use. Overall, Ventolin HFA remains a reliable choice for patients requiring inhaled beta2-agonists for asthma control.
Sources and full results
Most relevant research papers on this topic
Protection against methacholine bronchoconstriction to assess relative potency of inhaled beta2-agonist.
Proventil-HFA salbutamol is bioequivalent to Ventolin-CFC salbutamol, with 100- and 200-microgram doses being sufficient for bronchoprotection against methacholine bronchoconstriction.
RCTProventil HFA and ventolin have similar safety profiles during regular use.
Proventil HFA and Ventolin have similar safety profiles during regular use, with both not causing asthma control to deteriorate during regular use.
RCTSwitching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma.
Switching from Ventolin CFC to Ventolin HFA maintains comparable asthma control with a similar safety profile in patients.
RCT
Large Human TrialProventil HFA provides bronchodilation comparable to ventolin over 12 weeks of regular use in asthmatics.
Proventil HFA provides bronchodilation comparable to Ventolin and superior to HFA-134a placebo over 12 weeks of regular dosing, but response diminishes after 4 weeks.
RCTLarge Human TrialReal-world assessment of a metered-dose inhaler with integrated dose counter.
Integrated dose counters in metered-dose inhalers are a useful and reliable tool for accurately tracking medication use and preventing medication running out.
Non-RCTLarge Human TrialSafety and Efficacy of a New Albuterol Hydrofluoroalkane Formulation for Treating Asthma Symptoms in Children Two to Less Than Four Years of Age
Albuterol HFA is safe and effective for treating asthma symptoms in children aged 2 to less than 4 years, but not for children aged 4 years or older.
RCTClinical comparability of ventolin formulated with hydrofluoroalkane or conventional chlorofluorocarbon propellants in children with asthma.
Ventolin HFA is clinically comparable to Ventolin formulated with conventional CFC-containing propellant in treating asthma in children.
RCTProventil HFA provides protection from exercise-induced bronchoconstriction comparable to proventil and ventolin.
Proventil HFA provides comparable protection against exercise-induced bronchoconstriction to Ventolin and Proventil, with a safer profile compared to placebo.
RCTEquivalence of as-required salbutamol propelled by propellants 11 and 12 or HFA 134a in mild to moderate asthmatics. German Study Group.
As-required salbutamol 100 microg administered via a HFA 134a pMDI is as effective and safe as the currently available CFC-propelled formulation in mild to moderate asthmatics.
RCTLarge Human TrialAlbuterol HFA is as effective as albuterol CFC in preventing exercise-induced bronchoconstriction.
Albuterol HFA and CFC are equally effective and safe in preventing exercise-induced bronchospasm in asthmatic patients, with no significant difference in efficacy or safety.
RCT